Janus kinases are very promising targets whose inhibitors are poised to be the next generation of revolutionary drugs for the treatment of inflammatory, autoimmune and oncology diseases after biologics.

UR-67767 is a balanced Jak selective inhibitor with the potential to become the future drug of choice in the treatment of autoimmune disorders such as rheumatoid arthritis, thanks to its balanced equipotency for all Jak isoenzymes, high selectivity in the human kinome, nanomolar activity in human cells, excellent efficacy in animal models of disease, and wide safety margin.

The candidate selection process has generated other assets including: (i) a lead optimization program based on the dual Jak/Syk inhibition, and (ii) an early-stage Syk-specific program with compounds with very promising profiles.

Palau is seeking to establish creative and value-driven strategic alliances with leading biotechnology and pharmaceutical companies for this project.